Phage Therapy Market Size, Share and Growth Outlook 2026: By Phage Type, By Targeted Bacteria, By Mode of Administration, By Application, By Disease Indication, By End User, Companies to 2034
The global Phage Therapy Market size is forecast to increase from $48.58 Million in 2026 to $161.48 Million in 2034 at a CAGR of 16.2% between 2026 and 2034.
The Phage Therapy market report provides detailed analysis and outlook of Phage Therapy segments including By Phage Type (Natural Lytic Phages, Genetically Engineered / Synthetic Phages, Phage Cocktails, Endolysins and Phage-derived Enzymes), By Targeted Bacteria (Escherichia coli, Staphylococcus aureus, Streptococcus spp., Pseudomonas aeruginosa, Salmonella spp., Klebsiella pneumoniae, Others), By Mode of Administration (Oral, Topical, Injectable (IV/IM), Inhalation / Nebulized), By Application (Infectious Diseases, Antibacterial Resistance Mitigation, Biofilm Infections, Veterinary Applications, Aquaculture and Agriculture), By Disease Indication (Urinary Tract Infections, Chronic Otitis, Dental and Oral Infections, Chronic Ulcerative Colitis, Bone and Joint Infections, Wound and Skin Infections, Cystic Fibrosis Lung Infections, Others), By End User (Hospitals and Clinics, Agricultural Enterprises, Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Phage Therapy Industry Overview
Precision Bacteriophage Therapeutics Advancing Antimicrobial Innovation
The phage therapy industry is gaining momentum as biotechnology companies accelerate the development of targeted bacteriophage therapeutics for treating antibiotic-resistant bacterial infections. Increasing antimicrobial resistance has intensified interest in phage-based medicines that selectively eliminate pathogenic bacteria while preserving beneficial microbiota. Companies are expanding clinical pipelines, strengthening manufacturing capabilities, and investing in molecular characterization to improve product consistency, regulatory readiness, and long-term commercial scalability. Advances in phage selection, genomic analysis, companion diagnostics, and Good Manufacturing Practice (GMP) production are positioning phage therapy as an emerging precision medicine approach across respiratory, infectious disease, and hospital-acquired infection indications.
Scientific Research and Manufacturing Strengthening Clinical Development
Biotechnology companies continue to reinforce phage therapy development through advanced structural biology and collaborative manufacturing initiatives. Armata Pharmaceuticals, Inc. published detailed structural biology research describing near-atomic imaging of Pakpunavirus P7-1, a key component of its multi-phage therapeutic candidate AP-PA02 for chronic antibiotic-resistant Pseudomonas aeruginosa respiratory infections in cystic fibrosis and non-cystic fibrosis bronchiectasis patients. The findings improve understanding of virion stability and genome ejection mechanisms, supporting lifecycle management and long-term cGMP manufacturing stability. PHAXIAM Therapeutics and Technophage established an exclusive European collaboration to develop an Individualized Phage Therapies operational framework by combining their GMP phage portfolios targeting Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli. The partnership integrates PHAXIAM's Phage-Susceptibility-Testing phagogram diagnostics with Technophage's cGMP manufacturing expertise while allowing both organizations to continue their independent clinical development programs.
Clinical Progress Expanding Therapeutic Applications
Clinical advancement remains a major driver of innovation within the phage therapy industry. BiomX Inc. initiated patient dosing in its randomized, double-blind Phase 2b clinical trial evaluating BX004, a nebulized inhaled multi-phage cocktail developed for chronic Pseudomonas aeruginosa pulmonary infections in cystic fibrosis patients. The multicenter study is evaluating reductions in bacterial burden alongside improvements in lung function measured by forced expiratory volume (FEV1). Supported by additional capital funding, the company has extended its operational runway through the anticipated release of top-line clinical results. These ongoing clinical programs demonstrate the industry's commitment to developing targeted biological therapies capable of addressing multidrug-resistant bacterial infections through precision bacteriophage technology.
Phage Therapy Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Phage Therapy market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Locus Biosciences, IntraLytix, Inc., Micreos Human Health, BiomX, Adaptive Phage Therapeutics, BioChimpharm, Technophage, Microgen, Accelerated Health Systems LLC, Arthur Andrew Medical. The Phage Therapy market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Phage Therapy industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Phage Therapy industry include- Locus Biosciences, IntraLytix, Inc., Micreos Human Health, BiomX, Adaptive Phage Therapeutics, BioChimpharm, Technophage, Microgen, Accelerated Health Systems LLC, Arthur Andrew Medical. The Phage Therapy market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Phage Therapy Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Phage Therapy market remains one of the strongest-performing segments in the country.
The US Phage Therapy Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Phage Therapy market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Phage Therapy industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Phage Therapy markets
Canada's strong Phage Therapy sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Phage Therapy market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Phage Therapy Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Phage Therapy market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Phage Therapy population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Phage Therapy industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Phage Therapy market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Phage Therapy sales through 2034
France Phage Therapy companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Phage Therapy Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Phage Therapy distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Phage Therapy Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Phage Therapy market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Phage Therapy industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Phage Therapy industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Phage Therapy Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Phage Therapy market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Phage Therapy market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Phage Therapy Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Phage Therapy Market Segmentation
By Phage Type
Natural Lytic Phages
Genetically Engineered / Synthetic Phages
Phage Cocktails
Endolysins and Phage-derived Enzymes
By Targeted Bacteria
Escherichia coli
Staphylococcus aureus
Streptococcus spp.
Pseudomonas aeruginosa
Salmonella spp.
Klebsiella pneumoniae
Others
By Mode of Administration
Oral
Topical
Injectable (IV/IM)
Inhalation / Nebulized
By Application
Infectious Diseases
Antibacterial Resistance Mitigation
Biofilm Infections
Veterinary Applications
Aquaculture and Agriculture
By Disease Indication
Urinary Tract Infections
Chronic Otitis
Dental and Oral Infections
Chronic Ulcerative Colitis
Bone and Joint Infections
Wound and Skin Infections
Cystic Fibrosis Lung Infections
Others
By End User
Hospitals and Clinics
Agricultural Enterprises
Research Institutes
Leading Companies in Phage Therapy Industry (2026)
Locus Biosciences
IntraLytix, Inc.
Micreos Human Health
BiomX
Adaptive Phage Therapeutics
BioChimpharm
Technophage
Microgen
Accelerated Health Systems LLC
Arthur Andrew Medical
Countries Included
The Phage Therapy market report provides detailed analysis and outlook of Phage Therapy segments including By Phage Type (Natural Lytic Phages, Genetically Engineered / Synthetic Phages, Phage Cocktails, Endolysins and Phage-derived Enzymes), By Targeted Bacteria (Escherichia coli, Staphylococcus aureus, Streptococcus spp., Pseudomonas aeruginosa, Salmonella spp., Klebsiella pneumoniae, Others), By Mode of Administration (Oral, Topical, Injectable (IV/IM), Inhalation / Nebulized), By Application (Infectious Diseases, Antibacterial Resistance Mitigation, Biofilm Infections, Veterinary Applications, Aquaculture and Agriculture), By Disease Indication (Urinary Tract Infections, Chronic Otitis, Dental and Oral Infections, Chronic Ulcerative Colitis, Bone and Joint Infections, Wound and Skin Infections, Cystic Fibrosis Lung Infections, Others), By End User (Hospitals and Clinics, Agricultural Enterprises, Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Phage Therapy Industry Overview
Precision Bacteriophage Therapeutics Advancing Antimicrobial Innovation
The phage therapy industry is gaining momentum as biotechnology companies accelerate the development of targeted bacteriophage therapeutics for treating antibiotic-resistant bacterial infections. Increasing antimicrobial resistance has intensified interest in phage-based medicines that selectively eliminate pathogenic bacteria while preserving beneficial microbiota. Companies are expanding clinical pipelines, strengthening manufacturing capabilities, and investing in molecular characterization to improve product consistency, regulatory readiness, and long-term commercial scalability. Advances in phage selection, genomic analysis, companion diagnostics, and Good Manufacturing Practice (GMP) production are positioning phage therapy as an emerging precision medicine approach across respiratory, infectious disease, and hospital-acquired infection indications.
Scientific Research and Manufacturing Strengthening Clinical Development
Biotechnology companies continue to reinforce phage therapy development through advanced structural biology and collaborative manufacturing initiatives. Armata Pharmaceuticals, Inc. published detailed structural biology research describing near-atomic imaging of Pakpunavirus P7-1, a key component of its multi-phage therapeutic candidate AP-PA02 for chronic antibiotic-resistant Pseudomonas aeruginosa respiratory infections in cystic fibrosis and non-cystic fibrosis bronchiectasis patients. The findings improve understanding of virion stability and genome ejection mechanisms, supporting lifecycle management and long-term cGMP manufacturing stability. PHAXIAM Therapeutics and Technophage established an exclusive European collaboration to develop an Individualized Phage Therapies operational framework by combining their GMP phage portfolios targeting Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli. The partnership integrates PHAXIAM's Phage-Susceptibility-Testing phagogram diagnostics with Technophage's cGMP manufacturing expertise while allowing both organizations to continue their independent clinical development programs.
Clinical Progress Expanding Therapeutic Applications
Clinical advancement remains a major driver of innovation within the phage therapy industry. BiomX Inc. initiated patient dosing in its randomized, double-blind Phase 2b clinical trial evaluating BX004, a nebulized inhaled multi-phage cocktail developed for chronic Pseudomonas aeruginosa pulmonary infections in cystic fibrosis patients. The multicenter study is evaluating reductions in bacterial burden alongside improvements in lung function measured by forced expiratory volume (FEV1). Supported by additional capital funding, the company has extended its operational runway through the anticipated release of top-line clinical results. These ongoing clinical programs demonstrate the industry's commitment to developing targeted biological therapies capable of addressing multidrug-resistant bacterial infections through precision bacteriophage technology.
Phage Therapy Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Phage Therapy market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Locus Biosciences, IntraLytix, Inc., Micreos Human Health, BiomX, Adaptive Phage Therapeutics, BioChimpharm, Technophage, Microgen, Accelerated Health Systems LLC, Arthur Andrew Medical. The Phage Therapy market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Phage Therapy industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Phage Therapy Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Phage Therapy companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Phage Therapy markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Phage Therapy industry include- Locus Biosciences, IntraLytix, Inc., Micreos Human Health, BiomX, Adaptive Phage Therapeutics, BioChimpharm, Technophage, Microgen, Accelerated Health Systems LLC, Arthur Andrew Medical. The Phage Therapy market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Phage Therapy Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Phage Therapy market remains one of the strongest-performing segments in the country.
The US Phage Therapy Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Phage Therapy market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Phage Therapy industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Phage Therapy markets
Canada's strong Phage Therapy sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Phage Therapy market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Phage Therapy Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Phage Therapy market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Phage Therapy population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Phage Therapy industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Phage Therapy market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Phage Therapy sales through 2034
France Phage Therapy companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Phage Therapy Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Phage Therapy distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Phage Therapy Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Phage Therapy market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Phage Therapy industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Phage Therapy industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Phage Therapy Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Phage Therapy market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Phage Therapy market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Phage Therapy Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Phage Therapy Market Segmentation
By Phage Type
Natural Lytic Phages
Genetically Engineered / Synthetic Phages
Phage Cocktails
Endolysins and Phage-derived Enzymes
By Targeted Bacteria
Escherichia coli
Staphylococcus aureus
Streptococcus spp.
Pseudomonas aeruginosa
Salmonella spp.
Klebsiella pneumoniae
Others
By Mode of Administration
Oral
Topical
Injectable (IV/IM)
Inhalation / Nebulized
By Application
Infectious Diseases
Antibacterial Resistance Mitigation
Biofilm Infections
Veterinary Applications
Aquaculture and Agriculture
By Disease Indication
Urinary Tract Infections
Chronic Otitis
Dental and Oral Infections
Chronic Ulcerative Colitis
Bone and Joint Infections
Wound and Skin Infections
Cystic Fibrosis Lung Infections
Others
By End User
Hospitals and Clinics
Agricultural Enterprises
Research Institutes
Leading Companies in Phage Therapy Industry (2026)
Locus Biosciences
IntraLytix, Inc.
Micreos Human Health
BiomX
Adaptive Phage Therapeutics
BioChimpharm
Technophage
Microgen
Accelerated Health Systems LLC
Arthur Andrew Medical
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Phage Therapy Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Phage Therapy Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL PHAGE THERAPY MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Phage Therapy Markets in 2026
3.2. Global Historic and Forecast Phage Therapy Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Phage Therapy Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Phage Therapy Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Phage Therapy Value Chain
CHAPTER 4- PHAGE THERAPY MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Phage Therapy Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- PHAGE THERAPY MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Phage Type
Natural Lytic Phages
Genetically Engineered / Synthetic Phages
Phage Cocktails
Endolysins and Phage-derived Enzymes
By Targeted Bacteria
Escherichia coli
Staphylococcus aureus
Streptococcus spp.
Pseudomonas aeruginosa
Salmonella spp.
Klebsiella pneumoniae
Others
By Mode of Administration
Oral
Topical
Injectable (IV/IM)
Inhalation / Nebulized
By Application
Infectious Diseases
Antibacterial Resistance Mitigation
Biofilm Infections
Veterinary Applications
Aquaculture and Agriculture
By Disease Indication
Urinary Tract Infections
Chronic Otitis
Dental and Oral Infections
Chronic Ulcerative Colitis
Bone and Joint Infections
Wound and Skin Infections
Cystic Fibrosis Lung Infections
Others
By End User
Hospitals and Clinics
Agricultural Enterprises
Research Institutes
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA PHAGE THERAPY MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Phage Therapy Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Phage Therapy Market Trends and Growth Opportunities to 2034
7.5. North America Phage Therapy Market Size Outlook by Type
7.6. North America Phage Therapy Market Size Outlook by Application
7.7. North America Phage Therapy Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Phage Therapy Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Phage Therapy Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Phage Therapy Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Phage Therapy Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Phage Therapy Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Phage Therapy Companies
CHAPTER 8- EUROPE PHAGE THERAPY MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Phage Therapy Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Phage Therapy Market Trends and Growth Opportunities to 2034
8.5. Europe Phage Therapy Market Size Outlook by Type
8.6. Europe Phage Therapy Market Size Outlook by Application
8.7. Europe Phage Therapy Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Phage Therapy Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Phage Therapy Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Phage Therapy Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Phage Therapy Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Phage Therapy Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Phage Therapy Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Phage Therapy Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Phage Therapy Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Phage Therapy Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Phage Therapy Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Phage Therapy Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Phage Therapy Companies
CHAPTER 9- ASIA PACIFIC PHAGE THERAPY MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Phage Therapy Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Phage Therapy Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Phage Therapy Market Size Outlook by Type
9.6. Asia Pacific Phage Therapy Market Size Outlook by Application
9.7. Asia Pacific Phage Therapy Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Phage Therapy Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Phage Therapy Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Phage Therapy Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Phage Therapy Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Phage Therapy Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Phage Therapy Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Phage Therapy Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Phage Therapy Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Phage Therapy Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Phage Therapy Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Phage Therapy Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Phage Therapy Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA PHAGE THERAPY MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Phage Therapy Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Phage Therapy Market Trends and Growth Opportunities to 2034
10.5. South and Central America Phage Therapy Market Size Outlook by Type
10.6. South and Central America Phage Therapy Market Size Outlook by Application
10.7. South and Central America Phage Therapy Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Phage Therapy Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Phage Therapy Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Phage Therapy Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Phage Therapy Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Phage Therapy Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Phage Therapy Companies
CHAPTER 11- MIDDLE EAST AND AFRICA PHAGE THERAPY MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Phage Therapy Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Phage Therapy Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Phage Therapy Market Size Outlook by Type
11.6. Middle East and Africa Phage Therapy Market Size Outlook by Application
11.7. Middle East and Africa Phage Therapy Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Phage Therapy Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Phage Therapy Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Phage Therapy Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Phage Therapy Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Phage Therapy Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Phage Therapy Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Phage Therapy Industry
Locus Biosciences
IntraLytix, Inc.
Micreos Human Health
BiomX
Adaptive Phage Therapeutics
BioChimpharm
Technophage
Microgen
Accelerated Health Systems LLC
Arthur Andrew Medical
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Phage Therapy Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Phage Therapy Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL PHAGE THERAPY MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Phage Therapy Markets in 2026
3.2. Global Historic and Forecast Phage Therapy Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Phage Therapy Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Phage Therapy Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Phage Therapy Value Chain
CHAPTER 4- PHAGE THERAPY MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Phage Therapy Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- PHAGE THERAPY MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Phage Type
Natural Lytic Phages
Genetically Engineered / Synthetic Phages
Phage Cocktails
Endolysins and Phage-derived Enzymes
By Targeted Bacteria
Escherichia coli
Staphylococcus aureus
Streptococcus spp.
Pseudomonas aeruginosa
Salmonella spp.
Klebsiella pneumoniae
Others
By Mode of Administration
Oral
Topical
Injectable (IV/IM)
Inhalation / Nebulized
By Application
Infectious Diseases
Antibacterial Resistance Mitigation
Biofilm Infections
Veterinary Applications
Aquaculture and Agriculture
By Disease Indication
Urinary Tract Infections
Chronic Otitis
Dental and Oral Infections
Chronic Ulcerative Colitis
Bone and Joint Infections
Wound and Skin Infections
Cystic Fibrosis Lung Infections
Others
By End User
Hospitals and Clinics
Agricultural Enterprises
Research Institutes
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA PHAGE THERAPY MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Phage Therapy Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Phage Therapy Market Trends and Growth Opportunities to 2034
7.5. North America Phage Therapy Market Size Outlook by Type
7.6. North America Phage Therapy Market Size Outlook by Application
7.7. North America Phage Therapy Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Phage Therapy Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Phage Therapy Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Phage Therapy Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Phage Therapy Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Phage Therapy Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Phage Therapy Companies
CHAPTER 8- EUROPE PHAGE THERAPY MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Phage Therapy Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Phage Therapy Market Trends and Growth Opportunities to 2034
8.5. Europe Phage Therapy Market Size Outlook by Type
8.6. Europe Phage Therapy Market Size Outlook by Application
8.7. Europe Phage Therapy Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Phage Therapy Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Phage Therapy Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Phage Therapy Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Phage Therapy Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Phage Therapy Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Phage Therapy Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Phage Therapy Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Phage Therapy Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Phage Therapy Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Phage Therapy Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Phage Therapy Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Phage Therapy Companies
CHAPTER 9- ASIA PACIFIC PHAGE THERAPY MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Phage Therapy Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Phage Therapy Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Phage Therapy Market Size Outlook by Type
9.6. Asia Pacific Phage Therapy Market Size Outlook by Application
9.7. Asia Pacific Phage Therapy Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Phage Therapy Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Phage Therapy Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Phage Therapy Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Phage Therapy Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Phage Therapy Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Phage Therapy Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Phage Therapy Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Phage Therapy Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Phage Therapy Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Phage Therapy Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Phage Therapy Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Phage Therapy Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA PHAGE THERAPY MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Phage Therapy Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Phage Therapy Market Trends and Growth Opportunities to 2034
10.5. South and Central America Phage Therapy Market Size Outlook by Type
10.6. South and Central America Phage Therapy Market Size Outlook by Application
10.7. South and Central America Phage Therapy Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Phage Therapy Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Phage Therapy Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Phage Therapy Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Phage Therapy Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Phage Therapy Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Phage Therapy Companies
CHAPTER 11- MIDDLE EAST AND AFRICA PHAGE THERAPY MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Phage Therapy Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Phage Therapy Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Phage Therapy Market Size Outlook by Type
11.6. Middle East and Africa Phage Therapy Market Size Outlook by Application
11.7. Middle East and Africa Phage Therapy Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Phage Therapy Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Phage Therapy Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Phage Therapy Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Phage Therapy Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Phage Therapy Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Phage Therapy Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Phage Therapy Industry
Locus Biosciences
IntraLytix, Inc.
Micreos Human Health
BiomX
Adaptive Phage Therapeutics
BioChimpharm
Technophage
Microgen
Accelerated Health Systems LLC
Arthur Andrew Medical
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
